Ion channels as novel therapeutic targets in the treatment of pain

Journal of Pharmacy and Pharmacology

Volumn 62, Issue 9, 2010, Pages 1089-1095

  Mathie, Alistair ^a  

^a MEDWAY SCHOOL OF PHARMACY   (United Kingdom)

Author keywords

channelopathy; hERG; high throughput electrophysiology; ion channels; NaV1.7; P2X4; pain; TREK1; TRESK; TRPV1

Indexed keywords

(5 TERT BUTYL 2,3 DIHYDRO 1H INDEN 1 YL) 3 (1H INDAZOL 4 YL)UREA; 1 (2 BROMOPHENYL) 3 [1 (5 TRIFLUOROMETHYL 2 PYRIDINYL) 3 PYRROLIDINYL]UREA; AMIODARONE; ANALGESIC AGENT; BENZODIAZEPINE DERIVATIVE; CAPSAICIN; CARBAMAZEPINE; CYCLOOXYGENASE 2 INHIBITOR; DIAZOXIDE; ETHOSUXIMIDE; GRC 6211; ION CHANNEL; LAMOTRIGINE; LIDOCAINE; LUBIPROSTONE; MEMANTINE; MINOXIDIL; MK 2295; N [4 [6 [4 (TRIFLUOROMETHYL)PHENYL] 4 PYRIMIDINYLOXY]BENZOTHIAZOL 2 YL]ACETAMIDE; NARCOTIC ANALGESIC AGENT; NIFEDIPINE; NONSTEROID ANTIINFLAMMATORY AGENT; ONDANSETRON; PHENYTOIN; SODIUM CHANNEL BLOCKING AGENT; SULFONYLUREA DERIVATIVE; SUXAMETHONIUM; UNCLASSIFIED DRUG; VARENICLINE; VECURONIUM; VERAPAMIL;

ACTION POTENTIAL; ANXIETY DISORDER; CHANNELOPATHY; CLINICAL TRIAL; CONSTIPATION; DEMENTIA; DIABETES MELLITUS; DRUG MEGADOSE; DRUG TARGETING; EPILEPSY; GENE MUTATION; GENERAL ANESTHESIA; HEART ARRHYTHMIA; HIGH THROUGHPUT SCREENING; HUMAN; HYPERTENSION; LOCAL ANESTHESIA; LOW DRUG DOSE; MALE TYPE ALOPECIA; MOLECULAR CLOCK; NEUROPATHIC PAIN; NOCICEPTION; NONHUMAN; PAIN; PERIPHERAL NERVE; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; SENSORY NERVE CELL; TOBACCO DEPENDENCE;

ANIMALS; DRUG DISCOVERY; HUMANS; ION CHANNELS; PAIN; POTASSIUM CHANNELS; SODIUM CHANNELS; TRANSIENT RECEPTOR POTENTIAL CHANNELS;

EID: 77955239085     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2010.01131.x     Document Type: Review

References (82)

1. Hodgkin AL, Huxley AF. Currents carried by sodium and potassium ions through the membrane of the giant axon of Loligo. J Physiol 1952 116 : 449 472.
2. Hodgkin AL, Huxley AF. The components of membrane conductance in the giant axon of Loligo. J Physiol 1952 116 : 473 496.
3. Hamill OP et al. Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pflugers Arch 1981 391 : 85 100.
4. Hille B. Ion channel of excitable membranes. 3rd edn, Sunderland MA : Sinauer, 2001.
5. Alexander SPH et al. Guide to Receptors and Channels (GRAC), 4th edn. Br J Pharmacol 2009 158 : S1 S254.
6. Overington JP et al. How many drug targets are there? Nat Rev Drug Discov 2006 5 : 993 996.
7. Yu FH et al. Overview of molecular relationships in the voltage-gated ion channel superfamily. Pharmacol Rev 2005 57 : 387 295.
8. Dunlop J et al. High-throughput electrophysiology: an emerging paradigm for ion channel screening and physiology. Nat Rev Drug Discov 2008 7 : 358 368.
9. Imming P et al. Drugs, their targets and the nature and number of drug targets. Nature Rev Drug Discov 2006 5 : 821 834.
10. Kaczorowski GJ et al. Ion channels as drug targets: the next GPCRs. J Gen Physiol 2008 131 : 399 405.
11. Curran ME et al. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 1995 80 : 795 803.
12. Sanguinetti MC, Tristani-Firouzi M. hERG potassium channels and cardiac arrhythmia. Nature 2006 440 : 463 469.
13. Redfern WS et al. Relationships between pre-clinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 2003 58 : 32 45.
14. Mitcheson JS et al. A structural basis for long QT syndrome. Proc Natl Acad Sci USA 2000 97 : 12329 12333.
15. Bennett PB, Guthrie HR. Trends in ion channel drug discovery: advances in screening technologies. Trends Biotechnol 2003 21 : 563 569.
16. Schroeder K et al. Ionworks HT: a new high throughput electrophysiology measurement platform. J Biomol Screen 2003 8 : 50 64.
17. Finkel A et al. Population patch clamp improves data consistency and success rates in the measurement of ionic currents. J Biomol Screen 2006 11 : 488 496.
18. Mathes C. Qpatch: the past, present and future of automated patch-clamp. Exp Opin Ther Targets 2006 10 : 319 327.
19. Milligan CJ et al. Robotic multiwell planar patch-clamp for native and primary mammalian cells. Nature Protocols 2009 4 : 244 255.
20. Ashcroft FM. Ion channels and disease. San Diego : Academic Press, 2000.
21. Ashcroft FM. From molecule to malady. Nature 2006 440 : 440 447.
22. Catterall WA et al. Inherited neuronal ion channelopathies: new windows on complex neurological diseases. J Neurosci 2008 28 : 11768 11777.
23. Brackenbury WJ, Isom LL. Voltage-gated Na+ channels: potential for beta subunits as therapeutic targets. Exp Opin Ther Targets 2008 12 : 1191 1203.
24. Wallace RH et al. Febrile seizures and generalized epilepsy associated with a mutation in the Na channel beta1 subunit gene SCN1B. Nature Gen 1998 19 : 366 370.
25. Browne DL et al. Episodic ataxia/myokymia syndrome is associated with point mutations in the potassium channel gene KCNA1. Nature Gen 1994 8 : 111 112.
26. Rajakulendran S et al. Episodic ataxia type 1: a neuronal potassium channelopathy. Neurotherapeutics 2007 4 : 258 266.
27. Cooper EC, Jan LY. M-channels: neurological diseases, neuromodulation, and drug development. Arch Neurol 2003 60 : 496 500.
28. Sabbadini M, Yost CS. Molecular Biology of background K channels: insights from K(2P) knockout mice. J Mol Biol 2009 385 : 1331 1344.
29. Heurteaux C et al. TREK-1: a K+ channel involved in neuroprotection and general anaesthesia. EMBO J 2004 23 : 2684 2695.
30. Heurteaux C et al. Deletion of the background potassium channel TREK-1 results in a depression resistant phenotype. Nature Neurosci 2006 9 : 1134 1141.
31. Davies LA et al. TASK channel deletion in mice causes primary hyperaldosteronism. Proc Natl Acad Sci USA 2008 105 : 2203 2208.
32. Heitzmann D et al. Invalidation of TASK1 potassium channels disrupts adrenal gland zonation and mineralocorticoid homeostasis. EMBO J 2008 27 : 179 187.
33. Lodge NJ, Li Y-W. Ion channels as potential targets for the treatment of depression. Curr Opin Drug Discov Dev 2008 11 : 633 641.
34. Bockenhauer D et al. Epilepsy, ataxia, sensorineural deafness tubulopathy and KCNJ10 mutations. N Engl J Med 2009 360 : 1960 1970.
35. Doyle DA et al. The structure of the potassium channel: molecular basis of K+ conduction and selectivity. Science 1998 280 : 69 77.
36. Jiang Y et al. Crystal structure and mechanism of a calcium gated potassium channel. Nature 2002 417 : 515 522.
37. + channel. Nature 2003 423 : 33 41.
38. Long SB et al. Crystal structure of a mammalian voltage-dependent Shaker family K+ channel. Science 2005 309 : 897 903.
39. England S, de Groot MJ. Subtype selective targeting of voltage-gated sodium channels. Br J Pharmacol 2009 158 : 1413 1425.
40. Caterina MJ et al. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 1997 389 : 816 824.
41. Bautista DM et al. Pungent agents from Szechuan peppers excite sensory neurons by inhibiting two-pore potassium channels. Nat Neurosci 2008 11 : 772 779.
42. Dib-Hajj SD et al. Voltage-gated sodium channels in pain states: role in pathophysiology and targets for treatment. Brain Res Rev 2009 60 : 65 83.
43. Cox JJ et al. An SCN9A channelopathy causes congenital inability to experience pain. Nature 2006 444 : 894 898.
44. Dib-Hajj SD et al. From genes to pain: Na(v)1.7 and human pain disorders. Trends Neurosci 2007 30 : 555 563.
45. Khakh BS, et al. International Union of Pharmacology XXIV. Current status of the nomenclature and properties of P2X receptors and their subunits. Pharmacol Rev 2001 53 : 107 118.
46. North RA. Molecular physiology of P2X receptors. Physiol Rev 2002 82 : 1013 1067.
47. Jarvis MF. The neural-glial purinergic receptor ensemble in chronic pain states. Trends Neurosci 2010 33 : 48 57.
48. Tsuda M, et al. P2X4 receptors induced in spinal microglia gate tactile allodynia after nerve injury, Nature 2003 424 : 778 783.
49. Tsuda M, et al. Pain and purinergic signaling. Brain Res Rev 2009 2010 63 : 222 232.
50. Kawate T et al. Crystal structure of the ATP-gated P2X(4) ion channel in the closed state. Nature 2009 460 : 592 598.
51. Cortright DN, Szallasi A. TRP channels and pain. Curr Pharm Des 2009 15 : 1736 1749.
52. Woolf CJ, Ma Q. Nociceptors: noxious stimulus detectors. Neuron 2007 55 : 353 364.
53. Jeffry JA et al. Selective targeting of TRPV1 expressing sensory nerve terminals in the spinal cord for long lasting analgesia. PLoS One 2009 4 : e7021.
54. Kym PR et al. Analgesic potential of TRPV1 antagonists. Biochem Pharmacol 2009 778 : 211 216.
55. Gunthorpe MJ, Chizh BA. Clinical development of TRPV1 antagonists: targeting a pivotal point in the pain pathway. Drug Discov Today 2009 14 : 56 67.
56. Bevan SA, Andersson DA. TRP channel antagonists for pain: opportunities beyond TRPV1. Curr Opin Invest Drugs 2009 10 : 655 663.
57. Patapoutian A et al. Transient receptor potential channels: targeting pain at the source. Nat Rev Drug Discov 2009 8 : 55 68.
58. Derry S et al. Topical capsaicin for tonic neuropathic pain in adults. Cochrane Database Syst Rev 2009 Oct 7; (4) CD 007393.
59. Knotkova H et al. Capsaicin (TRPV1 agonist) therapy for pain relief: farewell or revival? Clin J Pain 2008 24 : 142 154.
60. Kim D. Physiology and pharmacology of two-pore domain potassium channels. Curr Pharm Des 2005 11 : 2717 2736. (Pubitemid 41051880)
61. Goldstein SAN et al. International union of pharmacology. LV. Nomenclature and molecular relationships of two-P potassium channels. Pharmacol. Rev 2005 57 : 527 540.
62. + channels. Cell Biochem Biophys 2007 47 : 209 256.
63. + currents: two-pore domain potassium channels. Physiol Rev 2010 90 : 559 605.
64. Mathie A, Veale EL. Therapeutic potential of neuronal two pore domain potassium channel modulators. Curr Opin Invest Drugs 2007 8 : 555 562.
65. Mathie A. Mammalian K2P channels and their regulation by G protein coupled receptors. J Physiol 2007 578 : 377 385.
66. Honore E. The neuronal background K2P channels: focus on TREK1. Nature Rev Neurosci 2007 8 : 251 261.
67. Bayliss DA, Barrett PQ. Emerging roles for two-pore-domain potassium channels and their potential therapeutic impact. Trends in Pharmacol Sci 2008 29 : 566 575.
68. Alloui A et al. TREK-1 a K+ channel involved in polymodal pain perception. EMBO J 2006 25 : 2368 2376.
69. Sano Y et al. A novel two-pore domain K+ channel, TRESK, is localized in the spinal cord. J Biol Chem 2003 278 : 27406 27412.
70. Kang D, Kim D. TREK-2 (K2P10.1) and TRESK (K2P18.1) are major background K+ channels in dorsal root ganglion neurons. Am J Physiol Cell Physiol 2006 291 : C138 C146.
71. Dobler T et al. TRESK two-pore-domain K+ channels constitute a significant component of background potassium currents in murine dorsal root ganglion neurones. J Physiol 2007 585 : 867 879.
72. Czirjak G, Enyedi P. Targeting of calcineurin to an NFAT-like docking site is required for the calcium-dependent activation of the background K+ channel, TRESK. J Biol Chem 2006 281 : 14677 14682.
73. Sato Y et al. The differential effect of cyclosporine on hypnotic response and pain reaction in mice. Anesth Analg 2007 105 : 1489 1493.
74. Smith HS. Calcineurin as a nociceptor modulator. Pain Physician 2009 12 : E309 E318.
75. Clarke CE et al. The M1P1 loop of TASK3 K2P channels apposes the selectivity filter and influences channel function. J Biol Chem 2008 283 : 16985 16992.
76. Kennard L et al. Inhibition of the human two-pore domain potassium channel, TREK-1, by fluoxetine and its metabolite norfluoxetine. Br J Pharmacol 2005 144 : 821 829.
77. Belardetti F, Zamponi GW. Linking calcium-channel isoforms to potential therapies. Curr Opin Invest Drugs 2008 9 : 707 715.
78. Verkman AS, Galietta LJ. Chloride channels as drug targets. Nat Rev Drug Discov 2009 8 : 153 171.
79. Witchel HJ. The hERG potassium channel as a therapeutic target. Exp Opin Ther Targets 2007 11 : 321 336.
80. Dulhunty AF et al. Agonists and antagonists of the cardiac ryanodine receptor: potential therapeutic agents? Pharmacol Ther 113 : 247 263.
81. Matulenko MA et al. Voltage-gated sodium channels and pain. Curr Top Med Chem 2009 9 : 362 376.
82. Nilius B et al. Transient receptor potential (TRP) cation channels in disease. Physiol Rev 2008 165 217.